Clinical Trials · NCT05387603
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Lund University Hospital
- Enrollment
- 300
- Start date
- Nov 2022
- Locations
- 4 sites, Sweden
- Primary endpoint
- Median progression free survival (PFS) defined as time from randomization to radiological progression.